Table 2.
The association of chitotriosidase activity (nmol/mL/h) and neopterin levels (nmol/L) at presentation with tumor characteristics and short-term survival.
| Group of Patients (n = 39) | Neopterin (nmol/L) Yes* | Neopterin (nmol/L) No** | p-Value | Chitotriosidase (nmol/mL/h) Yes* | Chitotriosidase (nmol/mL/h) No** | p-Value |
|---|---|---|---|---|---|---|
| T34 vs. T12 (n = 23) | 8.47 (5.31–18.27) | 11.09 (8.43–13.72) | 1 | 280 (125–395) | 250 (220–295) | 1 |
| T4 vs. T123 (n = 29) | 7.12 (5.21–11.73) | 16.42 (7.25–25.62) | 0.1 | 255 (127.5–333.75) | 300 (145–400) | 0.45 |
| M1 vs. M0 (n = 11) | 7.11 (5.31–10.5) | 10.49 (5.61–20.95) | 0.21 | 230 (107.5–297.5) | 290 (137.5–400) | 0.23 |
| Death during the first 30 days (n = 3) | 7.12 (6.47–8.59) | 10.22 (5.21–19.55) | 0.54 | 490 (405–525) | 250 (127.5–367.5) | 0.12 |
| Death during the first year (n = 17) | 7.12 (5.33–16.22) | 10.22 (5.32–19.67) | 0.65 | 270 (170–360) | 270 (130–397.5) | 0.91 |
Yes*—values for subjects with more advanced T or M stage, or death within the first 30 days or the first year, respectively. No**—values for subjects with lower T stage, without metastasis and improved survival. Results are presented as median and interquartile range.